BACKGROUND: Previous studies suggest that the transient receptor potential vanilloid 1 (TRPV1) channel has a role in sepsis, but it is unclear whether its effect on survival and immune response is beneficial or harmful. METHODS: We studied the effects of genetic (Trpv1-knockout vs. wild-type [WT] mice) and pharmacologic disruption of TRPV1 with resiniferatoxin (an agonist) or capsazepine (an antagonist) on mortality, bacterial clearance, and cytokine expression during lipopolysaccharide or cecal ligation and puncture-induced sepsis. RESULTS: After cecal ligation and puncture, genetic disruption of TRPV1 in Trpv1-knockout versus WT mice was associated with increased mortality risk (hazard ratio, 2.17; 95% CI, 1.23-3.81; P = 0.01). Furthermore, pharmacologic disruption of TRPV1 with intrathecal resiniferatoxin, compared with vehicle, increased mortality risk (hazard ratio, 1.80; 95% CI, 1.05-3.2; P = 0.03) in WT, but not in Trpv1-knockout, mice. After lipopolysaccharide, neither genetic (Trpv1 knockout) nor pharmacologic disruption of TRPV1 with resiniferatoxin had significant effect on survival compared with respective controls. In contrast, after lipopolysaccharide, pharmacologic disruption of TRPV1 with capsazepine, compared with vehicle, increased mortality risk (hazard ratio, 1.92; 95% CI, 1.02-3.61; P = 0.04) in WT animals. Furthermore, after cecal ligation and puncture, increased mortality in resiniferatoxin-treated WT animals was associated with higher blood bacterial count (P = 0.0004) and higher nitrate/nitrite concentrations and down-regulation of tumor necrosis factor α expression (P = 0.004) compared with controls. CONCLUSIONS: Genetic or pharmacologic disruption of TRPV1 can affect mortality, blood bacteria clearance, and cytokine response in sepsis in patterns that may vary according to the sepsis-inducing event and the method of TRPV1 disruption.
BACKGROUND: Previous studies suggest that the transient receptor potential vanilloid 1 (TRPV1) channel has a role in sepsis, but it is unclear whether its effect on survival and immune response is beneficial or harmful. METHODS: We studied the effects of genetic (Trpv1-knockout vs. wild-type [WT] mice) and pharmacologic disruption of TRPV1 with resiniferatoxin (an agonist) or capsazepine (an antagonist) on mortality, bacterial clearance, and cytokine expression during lipopolysaccharide or cecal ligation and puncture-induced sepsis. RESULTS: After cecal ligation and puncture, genetic disruption of TRPV1 in Trpv1-knockout versus WT mice was associated with increased mortality risk (hazard ratio, 2.17; 95% CI, 1.23-3.81; P = 0.01). Furthermore, pharmacologic disruption of TRPV1 with intrathecal resiniferatoxin, compared with vehicle, increased mortality risk (hazard ratio, 1.80; 95% CI, 1.05-3.2; P = 0.03) in WT, but not in Trpv1-knockout, mice. After lipopolysaccharide, neither genetic (Trpv1 knockout) nor pharmacologic disruption of TRPV1 with resiniferatoxin had significant effect on survival compared with respective controls. In contrast, after lipopolysaccharide, pharmacologic disruption of TRPV1 with capsazepine, compared with vehicle, increased mortality risk (hazard ratio, 1.92; 95% CI, 1.02-3.61; P = 0.04) in WT animals. Furthermore, after cecal ligation and puncture, increased mortality in resiniferatoxin-treated WT animals was associated with higher blood bacterial count (P = 0.0004) and higher nitrate/nitrite concentrations and down-regulation of tumor necrosis factor α expression (P = 0.004) compared with controls. CONCLUSIONS: Genetic or pharmacologic disruption of TRPV1 can affect mortality, blood bacteria clearance, and cytokine response in sepsis in patterns that may vary according to the sepsis-inducing event and the method of TRPV1 disruption.
Authors: J B Davis; J Gray; M J Gunthorpe; J P Hatcher; P T Davey; P Overend; M H Harries; J Latcham; C Clapham; K Atkinson; S A Hughes; K Rance; E Grau; A J Harper; P L Pugh; D C Rogers; S Bingham; A Randall; S A Sheardown Journal: Nature Date: 2000-05-11 Impact factor: 49.962
Authors: Gabriel C Tender; Stuart Walbridge; Zoltan Olah; Laszlo Karai; Michael Iadarola; Edward H Oldfield; Russell R Lonser Journal: J Neurosurg Date: 2005-03 Impact factor: 5.115
Authors: Laszlo Karai; Dorothy C Brown; Andrew J Mannes; Stephen T Connelly; Jacob Brown; Michael Gandal; Ofer M Wellisch; John K Neubert; Zoltan Olah; Michael J Iadarola Journal: J Clin Invest Date: 2004-05 Impact factor: 14.808
Authors: Andrés Vazquez-Torres; Bruce A Vallance; Molly A Bergman; B Brett Finlay; Brad T Cookson; Jessica Jones-Carson; Ferric C Fang Journal: J Immunol Date: 2004-05-15 Impact factor: 5.422
Authors: Samuel P Wanner; Andras Garami; Eszter Pakai; Daniela L Oliveira; Narender R Gavva; Cândido C Coimbra; Andrej A Romanovsky Journal: Cell Cycle Date: 2012-01-15 Impact factor: 4.534
Authors: Nicole Y Lai; Melissa A Musser; Felipe A Pinho-Ribeiro; Pankaj Baral; Amanda Jacobson; Pingchuan Ma; David E Potts; Zuojia Chen; Donggi Paik; Salima Soualhi; Yiqing Yan; Aditya Misra; Kaitlin Goldstein; Valentina N Lagomarsino; Anja Nordstrom; Kisha N Sivanathan; Antonia Wallrapp; Vijay K Kuchroo; Roni Nowarski; Michael N Starnbach; Hailian Shi; Neeraj K Surana; Dingding An; Chuan Wu; Jun R Huh; Meenakshi Rao; Isaac M Chiu Journal: Cell Date: 2019-12-05 Impact factor: 41.582
Authors: Isabel Devesa; Rosa Planells-Cases; Gregorio Fernández-Ballester; José Manuel González-Ros; Antonio Ferrer-Montiel; Asia Fernández-Carvajal Journal: J Inflamm Res Date: 2011-05-24